Collagen VI as a driver and disease biomarker in human fibrosis.

The FEBS Journal
Lynn M WilliamsJagdeep Nanchahal

Abstract

Fibrosis of visceral organs such as the lungs, heart, kidneys and liver remains a major cause of morbidity and mortality and is also associated with many other disorders, including cancer and metabolic disease. In this review, we focus upon the microfibrillar collagen VI, which is present in the extracellular matrix (ECM) of most tissues. However, expression is elevated in numerous fibrotic conditions, such as idiopathic pulmonary disease (IPF), and chronic liver and kidney diseases. Collagen VI is composed of three subunits α1, α2 and α3, which can be replaced with alternate chains of α4, α5 or α6. The C-terminal globular domain (C5) of collagen VI α3 can be proteolytically cleaved to form a biologically active fragment termed endotrophin, which has been shown to actively drive fibrosis, inflammation and insulin resistance. Tissue biopsies have long been considered the gold standard for diagnosis and monitoring of progression of fibrotic disease. The identification of neoantigens from enzymatically processed collagen chains have revolutionised the biomarker field, allowing rapid diagnosis and evaluation of prognosis of numerous fibrotic conditions, as well as providing valuable clinical trial endpoint determinants. Collagen VI...Continue Reading

References

Mar 1, 1976·Brain : a Journal of Neurology·J Bethlem, G K Wijngaarden
Apr 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M ShahinS M Abdel Razek
Dec 1, 1990·Arthritis and Rheumatism·J PeltonenS A Jimenez
Dec 1, 1990·The Journal of Cell Biology·W B StallcupP Healy
Sep 1, 1989·European Journal of Biochemistry·M AumailleyR Timpl
Mar 1, 1986·The Journal of Cell Biology·E EngvallG Klier
Jan 1, 1985·Annals of the New York Academy of Sciences·J EngelR Timpl
Aug 1, 1984·European Journal of Biochemistry·H von der MarkR Timpl
Apr 15, 1981·Developmental Biology·J SasseK von der Mark
Dec 15, 1995·Journal of Molecular Biology·T SasakiR Timpl
Jun 1, 1995·American Journal of Respiratory and Critical Care Medicine·U SpecksR Timpl
Jun 2, 1995·The Journal of Biological Chemistry·A ColombattiP Bonaldo
Nov 1, 1993·Molecular Biology of the Cell·A Nishiyama, W B Stallcup
Mar 1, 1996·Neurology·G J JobsisM de Visser
May 1, 1996·The Histochemical Journal·G MagroM Lopes
May 15, 1997·The Biochemical Journal·M F HoylaertsJ Vermylen
May 29, 1997·The New England Journal of Medicine·B GerlingD Schuppan
Oct 23, 1997·The Journal of Biological Chemistry·H J KuoR W Glanville
Mar 24, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·V Groma
Apr 1, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·T SasakiM L Chu
Oct 12, 2000·The Journal of Biological Chemistry·J FitzgeraldJ F Bateman
Oct 19, 2000·The Journal of Biological Chemistry·S G BallC A Shuttleworth
Jan 3, 2001·Biopolymers·N P CamachoR Mendelsohn
Mar 22, 2001·The Journal of Biological Chemistry·C WibergD Heinegård
Aug 17, 2001·Annals of Neurology·I HiguchiM Osame
Nov 3, 2001·Matrix Biology : Journal of the International Society for Matrix Biology·P SabatelliS Squarzoni
Jan 12, 2002·Biochemical and Biophysical Research Communications·T AignerE Pöschl
May 7, 2002·American Journal of Human Genetics·Ercan DemirPascale Guicheney

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.